Fate Therapeutics Announces FDA Clearance of IND for Clinical Development of ...
The Company has built two adult stem cell modulation platforms: a hematopoietic stem cell (HSC) modulation platform, which seeks to optimize the therapeutic potential of HSCs for treating patients with hematologic malignancies and rare genetic ...
Wall Street Journal - Tue, 29 Jul 2014 12:52

Bevacizumab plus lomustine improved outcomes in recurrent glioblastoma
The majority of patients (87%; n=129) discontinued treatment due to progressive disease. ... After the lomustine dose was reduced to 90 mg/m2, hematologic toxicities in the combination arm were similar to those observed with single-agent lomustine.
Healio - Tue, 29 Jul 2014 23:11

Baylor Sammons Cancer Center Joins as Clinical Trial Site for Actinium's ...
M. Yair Levy, MD, Medical Director of Hematologic Malignancy Clinical Research, Baylor Research Institute, stated, "AML in the elderly is a disease that is difficult to treat with few therapeutic options. Through our participation, Baylor is pleased to ...
Wall Street Journal - Wed, 30 Jul 2014 03:52

Milestones in Hematology and Blood Diseases
In an effort to dispel blood disorders with novel therapeutic solutions, OMICS Group International, a leading Open access Publisher and the Science Conference Organizer, announces its 2nd International Conference on Hematology and Blood Disorders on ...
PR Web (press release) - Wed, 09 Jul 2014 00:02

Higher carfilzomib dose induced durable response in multiple myeloma
Four of 10 patients who underwent prior allogeneic transplant achieved at least a partial response. Six patients responded to treatment, progressed and had dexamethasone added to their treatment regimen. Four of those six achieved at least stable disease.
Healio - Tue, 29 Jul 2014 12:41

Celldex Therapeutics Announces Senior Leadership Promotions
He has supervised clinical efforts in adult hematologic malignancies and marrow transplantation and therapeutic antibodies and vaccines at the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) and worked with Dr. Ron Levy ...
MarketWatch - Wed, 30 Jul 2014 05:00

FDA clears Lorus' LOR-253 IND application for treatment of hematologic ...
Lorus Therapeutics Inc. (TSX: LOR) today announced that the Food and Drug Administration (FDA) completed its review and cleared the company's Investigational New Drug (IND) application of LOR-253 for the treatment of hematologic malignancies including ... - Mon, 28 Jul 2014 05:44

US FDA clears Lorus' IND application to begin LOR-253 clinical programme in ... - Tue, 29 Jul 2014 03:18

Lorus Therapeutics Receives FDA Clearance of IND to Initiate LOR-253 Clinical ...
Wall Street Journal - Mon, 28 Jul 2014 04:03

KaloBios Provides Update on KB001-A Partnership and Clinical Status
We will immediately embark on a process to identify a partner with a focus on infectious disease, hospital pharmaceuticals, or cystic fibrosis who can accelerate and financially support the pivotal studies for KB001-A. " Sanofi Pasteur agreed to ...
FierceBiotech - Mon, 28 Jul 2014 13:48

1  2  3  4  5  6  7  8    ->

Last update: April 2009